A double blind, placebo controlled trial evaluating pegylated recombinant human megakaryocyte growth and development factor (MGDF) as an adjunct to induction and consolidation therapy in patients with acute myeloid leukemia (AML)
A double blind, placebo controlled trial evaluating pegylated recombinant human megakaryocyte growth and development factor (MGDF) as an adjunct to induction and consolidation therapy in patients with acute myeloid leukemia (AML). ASH. 1998; 313 (#1283).